Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Financials 
Technical Analysis 0
BUY
Likes the pharmaceutical industry, as it is undervalued. In the long term, it will come back. They will have to cut costs dramatically over the next several years. Cheap. Pays a 4% yield. Defensive. Won’t have dramatic moves.
Paul Harris, CFAOwned
biotechnologypharmaceutical
TOP PICK
One for over 1, 2 and 3 years. Lost their major new blockbuster drug, but it wasn’t due on the market until Lipitor came off patent, 4 years out. Has $38 billion in cash and generates about $14 billion cash a year. Dividend yield of 3.9% and sees it going up a lot.
Norman LevineOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Aug 3/06. Down 4.2%.) Have sold their consumer products division and have a tremendous amount of cash coming in, giving them a very strong balance sheet. A Hold.
Ross HealyOwned
biotechnologypharmaceutical
BUY
Pharmaceutical and health care area has been very difficult. Has done better in the last 6 months. A cheap stock.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick July 11/06. Up 12.8%.) 3.6 % dividend. Still more upside. But pipeline. Money continues to flow into the multinationals, which will benefit this company.
Norman LevineOwned
biotechnologypharmaceutical
BUY
3.4% dividend. The stock has been steadily rising over the last four months. Should be a core holding.
Rob CallanderOwned
biotechnologypharmaceutical
HOLD
This group has been forgotten over the last 5 years as it wildly under-performed the market. They all went to virtually zero growth rate and now there is a pick up. There is cost cutting and they are under owned. Likes this space. This would not be his number one choice but it is okay.
biotechnologypharmaceutical
BUY
His favourite large drug stock. Has been beaten up pretty badly. Has a great product pipeline, even with patents coming off. Swimming in cash. Doing a share buyback and have increased their dividends.
Norman LevineOwned
biotechnologypharmaceutical
BUY
Very cheap. Pays a nice yield. There were some issues with management and there has been a change. The pharmaceutical industry as a whole is undervalued.
Paul Harris, CFAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
